首页> 外文期刊>Bone marrow transplantation >Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.
【24h】

Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

机译:重新评估了美国国立卫生研究院对慢性GVHD进行分类和评分的标准。

获取原文
获取原文并翻译 | 示例
           

摘要

We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-alone' patients, we re-categorized 216 patients in keeping with the NIH criteria. Twenty patients were reclassified as having acute GVHD and 196 patients as having cGVHD (170 'classic chronic' (Cl-Ch) and 26 'overlap chronic' (Ov-Ch)). The 5-year GVHD-specific survival (GSS) was significantly different between the two cGVHD subtypes, specifically 87.3% for Cl-Ch vs 70.2% for Ov-Ch (P=0.006). The NIH severity criteria were effective in expecting 5-year GSS rates at both the onset (93.5, 81.3 and 79.7% (P=0.047)) and peak intensity of the disease (100, 89.7 and 78.7% (P=0.004) for the mild, moderate and severe grade, respectively). Multivariate analysis showed that NIH severity criteria were independently significant prognostic factors for GSS (mild vs moderate, HR 4.35, P=0.036; mild vs severe, HR 5.25, P=0.020). Our results support the role of the NIH criteria in classifying cGVHD and in assessing the severity of the disease to predict patient prognosis of cGVHD.
机译:我们使用美国国立卫生研究院(NIH)的标准对慢性GVHD(cGVHD)进行诊断,分类和评分,以重新评估最初使用经典标准诊断的cGVHD患者。我们根据经典标准从236名诊断为cGVHD的患者中检索了数据。除20名“无肝”患者外,我们根据NIH标准对216名患者进行了重新分类。 20例患者被重新分类为急性GVHD,196例患者被重新分类为cGVHD(170例“经典慢性”(Cl-Ch)和26例“重叠慢性”(Ov-Ch))。两种cGVHD亚型的5年GVHD特异性存活率(GSS)显着不同,Cl-Ch分别为87.3%,Ov-Ch为70.2%(P = 0.006)。 NIH严重性标准可有效预测发病的5年GSS发生率(93.5、81.3和79.7%(P = 0.047))和疾病的峰值强度(100、89.7和78.7%(P = 0.004))。轻度,中度和重度)。多因素分析显示,NIH严重程度标准是GSS的独立重要预后因素(轻度vs中度,HR 4.35,P = 0.036;轻度vs重度,HR 5.25,P = 0.020)。我们的结果支持NIH标准在分类cGVHD和评估疾病严重程度以预测患者cGVHD预后方面的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号